With Psilocybin set to be more available for those with treatment-resistant depression comes the question of accessibility.

Currently only one specialist will be able to provide psilocybin to patients, with concerns over how much the treatment will cost.

News and Editorial Director and Monday Wire Host, Joel, spoke to Suresh Muthukumaraswamy, a Professor in the School of Pharmacy at the University of Auckland, about psilocybin, and what should be expected with allowing psilocybin to treat treatment-resistant depression.